GO:0016409 palmitoyltransferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0016409 (palmitoyltransferase activity) describes the catalysis of palmitoyl group transfer to an acceptor molecule, a reversible lipid modification that controls protein localization, stability and signaling.
• The term covers both protein S-palmitoyltransferases (ZDHHC family) and metabolic acyltransferases such as carnitine palmitoyltransferases (CPT1A/CPT2), which use palmitoyl-CoA as donor.
• Palmitoylation is essential for innate immune signaling: it drives NLRP3 phase separation and inflammasome activation and facilitates gasdermin D-mediated pyroptosis.
• Dysregulated palmitoyltransferase activity contributes to cancer, including colon tumorigenesis via ZDHHC6-PPARγ-lipid reprogramming and hepatocellular carcinoma via ZDHHC12-HDAC8 under high saturated fatty acid diets.
• CPT1A inhibition in hepatic stellate cells protects against fibrosis, showing that palmitoyltransferase activity is a druggable node in metabolic liver disease.
• CRISPR knockout, point-mutation, knock-in and overexpression models are the standard tools to dissect which palmitoyltransferase genes are causally involved in a given phenotype.
Description
Palmitoyltransferase activity (GO:0016409) is a molecular function defined as the catalysis of the transfer of a palmitoyl (CH3-[CH2]14-CO-) group to an acceptor molecule. This activity is central to lipid biology because it converts the abundant fatty acyl donor palmitoyl-CoA into covalent modifications on proteins and other acceptors, thereby changing their hydrophobicity, membrane affinity and interaction landscape. Long-chain fatty acids such as palmitate are not only fuels but also signaling molecules whose metabolism is tightly regulated by acyltransferases. Researchers study GO:0016409 to understand how cells route palmitate into energy production, membrane remodeling and post-translational modification, and how errors in these steps drive disease. Functionally, palmitoyltransferase activity spans two broad families. The first includes carnitine palmitoyltransferases, which attach palmitoyl groups to carnitine to shuttle fatty acids into mitochondria for beta-oxidation; CPT1A and CPT2 are the canonical enzymes in this axis. The second includes protein S-palmitoyltransferases of the ZDHHC family, which transfer palmitate to cysteine residues of substrate proteins and thereby control their membrane targeting and signaling. Both families use palmitoyl-CoA as the acyl donor and both are emerging therapeutic targets in metabolic disease and cancer. Because palmitoylation is reversible and dynamic, it acts as a switch in processes as diverse as inflammasome assembly, pyroptosis and lipid metabolic reprogramming. This article summarizes the QuickGO definition, the catalytic and regulatory logic of GO:0016409, the key genes involved, and the CRISPR-based research methods used to interrogate this activity in human disease models.
palmitoyltransferase activity At A Glance
| GO ID | GO:0016409 |
|---|---|
| GO term | palmitoyltransferase activity |
| Ontology | molecular_function |
| Synonym | (none) |
| Definition | Catalysis of the transfer of a palmitoyl (CH3-[CH2]14-CO-) group to an acceptor molecule. |
| Major function | Covalent attachment of palmitate to protein or small-molecule acceptors, controlling membrane targeting, trafficking and signaling |
| Representative enzymes | ZDHHC-family protein S-palmitoyltransferases and carnitine palmitoyltransferases (CPT1A, CPT2) |
| Acyl donor | Palmitoyl-CoA, a long-chain fatty acyl-CoA |
| Reaction type | Acyl transfer (acyltransferase chemistry) |
What Is GO:0016409?
GO:0016409, palmitoyltransferase activity, is the catalysis of the transfer of a palmitoyl (CH3-[CH2]14-CO-) group to an acceptor molecule. In practice, the enzyme binds palmitoyl-CoA and transfers the 16-carbon saturated acyl chain to a nucleophilic acceptor, which may be a protein cysteine thiol (S-palmitoylation) or a small molecule such as carnitine (O-palmitoylation). The reaction is a central node in fatty acid trafficking and in reversible lipid-based protein modification.
Why Is palmitoyltransferase activity Important in Cell Biology?
Palmitoyltransferase activity is important because it sits at the intersection of energy metabolism and signal transduction. On the metabolic side, carnitine palmitoyltransferases determine how much palmitate enters mitochondrial beta-oxidation, and their inhibition can protect against hepatic fibrosis. On the signaling side, protein S-palmitoylation controls the localization and function of immune and oncogenic proteins, including NLRP3, gasdermin D, PPARγ and HDAC8. Because the reaction is reversible and enzyme-catalyzed, it offers multiple points for pharmacological and genetic intervention, making GO:0016409 a high-value target class for cancer, metabolic and inflammatory disease research.
• Controls mitochondrial fatty acid import through CPT1A and CPT2, linking palmitoyltransferase activity to energy homeostasis.
• Drives innate immune activation by promoting NLRP3 phase separation and inflammasome assembly.
• Enables gasdermin D-mediated pyroptosis and cytokine release through palmitoylation at a conserved cysteine.
• Supports tumorigenesis: ZDHHC6 promotes colon cancer via PPARγ-driven lipid biosynthesis.
• Promotes hepatocellular carcinoma progression under high saturated fatty acid diets via ZDHHC12-mediated HDAC8 palmitoylation.
• Provides a druggable target in liver fibrosis, where CPT1A inhibition in hepatic stellate cells is protective.
• Regulates systemic lipid and energy metabolism through long-chain fatty acid sensing.
• Is relevant to exercise and muscle bioenergetics through carnitine-dependent acyl trafficking.
• Offers chemoproteomic entry points, as shown by baicalin activation of hepatic CPT1.
• Underpins reversible membrane targeting of signaling proteins, a general mechanism in cell biology.
Molecular Mechanism of palmitoyltransferase activity
Substrate recognition and acyl donor binding
In simple terms: The enzyme first grabs a palmitate-loaded carrier molecule called palmitoyl-CoA.
Palmitoyltransferase activity begins with binding of the acyl donor palmitoyl-CoA, a long-chain fatty acyl-CoA derived from dietary and endogenous fatty acids. Long-chain fatty acids such as palmitate are regulated at the level of their metabolism and can serve as substrates for acyltransferases. In the carnitine palmitoyltransferase branch, CPT1A and CPT2 recognize palmitoyl-CoA and carnitine to build palmitoylcarnitine for mitochondrial import. In the protein S-palmitoylation branch, ZDHHC enzymes bind palmitoyl-CoA and a protein substrate, as exemplified by ZDHHC6 and ZDHHC12.
Catalytic transfer to the acceptor
In simple terms: The enzyme hands the palmitate chain to its target, forming a new chemical bond.
The catalytic step transfers the palmitoyl group to a nucleophilic acceptor. For carnitine palmitoyltransferases, the acceptor is carnitine, yielding palmitoylcarnitine that feeds beta-oxidation. For protein palmitoyltransferases, the acceptor is typically a cysteine thiol on the substrate protein, producing a thioester-linked S-palmitoylated protein. Palmitoylation of gasdermin D at a conserved cysteine is required for its function in pyroptosis and cytokine release. Similarly, ZDHHC12 palmitoylates HDAC8 to promote hepatocellular carcinoma progression, and ZDHHC6-dependent palmitoylation supports PPARγ-driven lipid biosynthesis in colon cancer.
Consequences for protein localization and signaling
In simple terms: Adding palmitate acts like a sticky tag that sends proteins to membranes and changes what they do.
Palmitoylation increases hydrophobicity and membrane affinity, redirecting substrate proteins to specific cellular membranes and signaling platforms. This is critical for innate immunity: signal-induced NLRP3 phase separation initiates inflammasome activation, a process dependent on the modified protein state. Gasdermin D palmitoylation facilitates its membrane pore-forming activity during pyroptosis. In cancer cells, palmitoylation of PPARγ and HDAC8 rewires lipid metabolism and transcriptional programs that support tumor growth.
Reversibility and depalmitoylation balance
In simple terms: The palmitate tag can be removed again, so the system works like a reversible switch.
Palmitoylation is a reversible modification, and the steady-state level of a palmitoylated protein reflects the balance between palmitoyltransferase and depalmitoylase activities. This reversibility allows dynamic control of protein trafficking and signaling, as seen for gasdermin D and inflammasome components. Because the modification is enzyme-controlled, it is amenable to genetic and pharmacological perturbation, which is why palmitoyltransferase activity is studied with knockout and point-mutation models.
Metabolic integration with fatty acid oxidation
In simple terms: The same activity that tags proteins also decides how much fat gets burned for energy.
Carnitine palmitoyltransferase activity is the rate-limiting gateway for mitochondrial long-chain fatty acid oxidation. CPT1A inhibition in hepatic stellate cells protects against fibrosis, demonstrating that this acyl-transfer step has direct disease relevance. Chemoproteomic studies show that baicalin activates hepatic CPT1 to ameliorate diet-induced obesity and hepatic steatosis, linking small-molecule modulation of palmitoyltransferase activity to metabolic benefit. Carnitine availability further influences muscle bioenergetics and exercise performance, underscoring the physiological reach of this activity.
Key Genes Involved in GO:0016409 palmitoyltransferase activity
The following genes encode enzymes, substrates and regulators that define palmitoyltransferase activity (GO:0016409) in human cells and model organisms.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CPT1A | Liver-type carnitine palmitoyltransferase; gates mitochondrial long-chain fatty acid import | Inhibition in hepatic stellate cells protects against fibrosis; target for steatosis and obesity studies |
| CPT2 | Inner mitochondrial carnitine palmitoyltransferase | Completes the carnitine shuttle for palmitate oxidation |
| ZDHHC6 | Protein S-palmitoyltransferase acting on PPARγ pathway | Promotes colon tumorigenesis via lipidome reprogramming |
| ZDHHC12 | Protein S-palmitoyltransferase acting on HDAC8 | Drives hepatocellular carcinoma under high saturated fatty acid diets |
| NLRP3 | Inflammasome sensor whose activation depends on palmitoylation-linked phase separation | Model for innate immune activation |
| GSDMD | Gasdermin D pore-forming protein palmitoylated at a conserved cysteine | Required for pyroptosis and cytokine release |
| PPARγ | Nuclear receptor and substrate of ZDHHC6-dependent palmitoylation | Links palmitoylation to lipid biosynthesis in cancer |
| HDAC8 | Histone deacetylase palmitoylated by ZDHHC12 | Epigenetic effector in hepatocellular carcinoma |
| CPT1B | Muscle-type carnitine palmitoyltransferase | Relevant to muscle fatty acid oxidation and exercise bioenergetics |
| CPT1C | Brain-enriched carnitine palmitoyltransferase | Candidate for neuronal lipid handling studies |
| SLC25A20 | Carnitine-acylcarnitine translocase partnering with CPT enzymes | Supports the carnitine shuttle |
| ACSL1 | Long-chain acyl-CoA synthetase generating palmitoyl-CoA | Provides substrate for palmitoyltransferases |
| FASN | Fatty acid synthase producing palmitate | Upstream of palmitoyl-CoA pools |
| SCD1 | Stearoyl-CoA desaturase modifying saturated acyl chains | Modulates saturated fatty acid effects on palmitoylation |
| ZDHHC5 | Neuronal protein S-palmitoyltransferase | General model for ZDHHC substrate specificity |
| ZDHHC3 | Golgi-localized protein S-palmitoyltransferase | Model for secretory pathway palmitoylation |
| LYPLA1 | Depalmitoylase reversing protein palmitoylation | Counterbalances palmitoyltransferase activity |
| PPT1 | Palmitoyl-protein thioesterase | Lysosomal depalmitoylation relevant to neurodegeneration |
How Is palmitoyltransferase activity Regulated?
Palmitoyltransferase activity is regulated at multiple levels. Substrate supply is controlled by long-chain fatty acid availability and by enzymes such as ACSL1 and FASN that generate palmitoyl-CoA. In the carnitine palmitoyltransferase axis, CPT1A activity is sensitive to nutritional and pharmacological inputs; baicalin activates hepatic CPT1 to improve diet-induced obesity and steatosis, while CPT1A inhibition in hepatic stellate cells protects against fibrosis. Carnitine availability modulates muscle bioenergetics and exercise performance, indirectly tuning carnitine palmitoyltransferase flux. For protein S-palmitoylation, enzyme abundance and substrate accessibility regulate the modification; ZDHHC6 and ZDHHC12 expression levels correlate with tumor phenotypes, and the balance with depalmitoylases such as LYPLA1 and PPT1 determines steady-state palmitoylation. In innate immunity, signal-induced NLRP3 phase separation provides a regulated trigger for inflammasome activation that depends on the modified protein state.
palmitoyltransferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ZDHHC6 | Colon tumorigenesis via PPARγ-driven lipid biosynthesis | ZDHHC6 knockout and overexpression colon cancer cell lines with lipidomics |
| ZDHHC12 | Hepatocellular carcinoma associated with high saturated fatty acid diet | ZDHHC12 knockout hepatoma cells under palmitate loading |
| CPT1A | Hepatic fibrosis and steatosis | CPT1A inhibition or knockout in hepatic stellate cells and liver organoids |
| GSDMD | Pyroptosis and cytokine release | GSDMD cysteine point-mutant knock-in macrophages |
| NLRP3 | Inflammasome activation | NLRP3 knockout and phase-separation reporter macrophages |
Cancer and lipid metabolic reprogramming
Palmitoyltransferase activity supports tumorigenesis through lipid metabolic reprogramming. ZDHHC6 promotes colon tumorigenesis by targeting PPARγ-driven lipid biosynthesis, and its manipulation alters the lipidome of cancer cells. In hepatocellular carcinoma associated with a diet high in saturated fatty acids, ZDHHC12 palmitoylates HDAC8 to promote disease progression. These findings position GO:0016409 enzymes as candidate therapeutic targets and biomarkers in gastrointestinal and liver cancers.
Innate immunity and inflammatory cell death
Palmitoylation is required for key innate immune events. Signal-induced NLRP3 phase separation initiates inflammasome activation, a process linked to the palmitoylation-dependent state of the sensor. Gasdermin D palmitoylation at a conserved cysteine facilitates pyroptosis and cytokine release, making this modification a checkpoint in inflammatory cell death. Together these studies show that palmitoyltransferase activity can amplify or license inflammatory responses.
Metabolic liver disease and fibrosis
Carnitine palmitoyltransferase activity is central to hepatic fatty acid handling. Inhibition of CPT1A in hepatic stellate cells protects against fibrosis, indicating that blocking this acyl-transfer step can reduce fibrogenic activation. Chemoproteomic profiling shows that baicalin activates hepatic CPT1 to ameliorate diet-induced obesity and hepatic steatosis, providing a small-molecule proof of concept for modulating palmitoyltransferase activity in metabolic disease.
Muscle bioenergetics and exercise
Carnitine-dependent palmitoyl transfer supports muscle energy metabolism, and carnitine availability has been studied as a determinant of exercise performance. Because CPT1B and the carnitine shuttle govern long-chain fatty acid oxidation in muscle, alterations in palmitoyltransferase activity may influence fatigue resistance and metabolic flexibility.
From palmitoyltransferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a ZDHHC enzyme required for tumor growth? | CRISPR knockout of the ZDHHC gene in cancer cell lines followed by proliferation and lipidomics assays |
| Which cysteine residue accepts palmitate? | Point-mutation knock-in of the candidate cysteine to alanine in the substrate gene |
| Does a disease-associated variant alter palmitoylation? | Knock-in of the patient variant and comparison of palmitoylation levels |
| Where does the palmitoylated protein localize? | Tagged knock-in with a fluorescent or affinity tag for imaging and proteomics |
| Does overexpression mimic the disease phenotype? | Doxycycline-inducible overexpression of the palmitoyltransferase in target cells |
| Can a drug modulate the activity? | CRISPR-engineered reporter cells treated with small molecules such as baicalin |
How to Study the palmitoyltransferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss of enzyme function | Testing requirement of ZDHHC or CPT genes in disease models |
| Point-mutation knock-in | Specific residue contribution | Mapping the palmitoylated cysteine in gasdermin D |
| Overexpression | Gain-of-function phenotype | Driving tumorigenesis or lipid reprogramming |
| Lipidomics | Global lipid species changes | Characterizing ZDHHC6-dependent lipidome reprogramming |
| Chemoproteomics | Enzyme-small molecule interactions | Identifying CPT1 activators such as baicalin |
| Imaging / phase-separation assay | Protein localization and assembly | Monitoring NLRP3 inflammasome initiation |
| Respirometry / fatty acid oxidation flux | Mitochondrial substrate use | Assessing CPT1A-dependent beta-oxidation |
| Cytokine release assays | Inflammatory output | Linking gasdermin D palmitoylation to pyroptosis |
Genetic perturbation with CRISPR
CRISPR knockout, point mutation, knock-in and overexpression are used to establish causality between a palmitoyltransferase gene and a phenotype. For example, ZDHHC6 and ZDHHC12 have been interrogated by loss- and gain-of-function approaches in colon and liver cancer models, and cysteine point mutants of gasdermin D define the palmitoylation site required for pyroptosis.
Lipidomics and chemoproteomics
Because GO:0016409 transfers a lipid group, mass-spectrometry-based lipidomics and chemoproteomics are core methods. Lipidome metabolic reprogramming downstream of ZDHHC6 has been mapped in colon cancer cells, and chemoproteomics revealed that baicalin activates hepatic CPT1 to ameliorate diet-induced obesity and steatosis.
Imaging and phase-separation assays
Fluorescence imaging and phase-separation assays visualize how palmitoylation-dependent proteins assemble into signaling platforms. Signal-induced NLRP3 phase separation initiates inflammasome activation and can be monitored with tagged knock-in reporters. Membrane localization of palmitoylated gasdermin D is similarly tracked by imaging.
Metabolic flux and bioenergetic assays
Seahorse respirometry, fatty acid oxidation flux and carnitine supplementation studies measure the metabolic output of carnitine palmitoyltransferase activity. These assays complement genetic models and help distinguish effects on beta-oxidation from effects on protein palmitoylation.
How CRISPR Can Be Used to Study GO:0016409 palmitoyltransferase activity
Knockout
CRISPR knockout of palmitoyltransferase genes is the primary loss-of-function strategy. Knocking out ZDHHC6 or ZDHHC12 reduces tumorigenic phenotypes and alters lipid metabolism in cancer cells, while CPT1A knockout or inhibition in hepatic stellate cells protects against fibrosis. Knockout of NLRP3 or GSDMD blocks inflammasome and pyroptosis outputs linked to palmitoylation.
Point Mutation
Point-mutation knock-in is used to test the specific residue that accepts palmitate. Mutation of the conserved cysteine in gasdermin D abolishes palmitoylation and impairs pyroptosis and cytokine release. Similar strategies can test catalytic residues of ZDHHC enzymes or substrate acceptor sites in disease variants.
Knock-in
Knock-in of tags or disease alleles allows tracking and functional analysis of palmitoylated proteins. Tagged knock-in of NLRP3 enables imaging of signal-induced phase separation during inflammasome activation, and knock-in of patient variants can reveal altered palmitoylation of HDAC8 or PPARγ pathway components.
Overexpression
Overexpression models test whether increased palmitoyltransferase activity is sufficient to drive disease. Overexpressing ZDHHC6 promotes colon tumorigenesis via PPARγ-driven lipid biosynthesis, and overexpressing ZDHHC12 enhances hepatocellular carcinoma progression under high saturated fatty acid conditions. Inducible overexpression systems allow temporal control of these phenotypes.
How EDITGENE Supports palmitoyltransferase activity Research
Researchers studying palmitoyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in a phenotype, which requires precise, reproducible genome engineering rather than correlative observation. EDITGENE provides the full spectrum of CRISPR models needed to move from hypothesis to publication-grade evidence for GO:0016409 biology.
Contact EDITGENE today to design your custom CRISPR model for palmitoyltransferase activity research.
Frequently Asked Questions About palmitoyltransferase activity
What is palmitoyltransferase activity?
Palmitoyltransferase activity (GO:0016409) is the catalysis of the transfer of a palmitoyl (CH3-[CH2]14-CO-) group to an acceptor molecule, using palmitoyl-CoA as the acyl donor.
What genes are involved in palmitoyltransferase activity?
Key genes include CPT1A, CPT2, ZDHHC6, ZDHHC12 and substrate genes such as NLRP3, GSDMD, PPARγ and HDAC8.
What is the GO ID for palmitoyltransferase activity?
The Gene Ontology ID is GO:0016409, under the molecular_function aspect.
How does palmitoylation affect protein function?
Palmitoylation increases membrane affinity and controls protein localization and signaling, as shown for gasdermin D and NLRP3.
Is palmitoyltransferase activity involved in cancer?
Yes. ZDHHC6 promotes colon tumorigenesis via PPARγ-driven lipid biosynthesis, and ZDHHC12 palmitoylates HDAC8 to promote hepatocellular carcinoma.
What is the role of CPT1A in liver disease?
Inhibition of CPT1A in hepatic stellate cells protects against fibrosis, and CPT1 activation by baicalin ameliorates diet-induced obesity and steatosis.
How is palmitoylation linked to inflammation?
Palmitoylation supports signal-induced NLRP3 phase separation and inflammasome activation, and gasdermin D palmitoylation facilitates pyroptosis and cytokine release.
Which methods study palmitoyltransferase activity?
CRISPR knockout, point-mutation knock-in, overexpression, lipidomics, chemoproteomics, imaging and metabolic flux assays are commonly used.
Can palmitoyltransferase activity be inhibited pharmacologically?
Small molecules can modulate this activity; baicalin activates hepatic CPT1 to improve steatosis, and CPT1A inhibition protects against fibrosis.
Why use CRISPR models for palmitoyltransferase research?
CRISPR knockout, point mutation, knock-in and overexpression establish causality between a palmitoyltransferase gene and a phenotype, as demonstrated for ZDHHC6, ZDHHC12 and GSDMD.
Conclusion
Palmitoyltransferase activity (GO:0016409) is a molecular function that couples lipid metabolism to protein modification and signaling. Its enzymes, from carnitine palmitoyltransferases to ZDHHC-family S-palmitoyltransferases, control fatty acid oxidation, inflammasome activation, pyroptosis and tumor lipid reprogramming. Because the reaction is reversible and genetically tractable, it is an attractive target for both mechanistic studies and therapeutic development. CRISPR-based knockout, point-mutation, knock-in and overexpression models, combined with lipidomics and imaging, provide the causal evidence needed to translate palmitoyltransferase biology into clinical insight. EDITGENE supports these workflows with custom cell model generation and screening services tailored to GO:0016409 research.
References
- 1. Zou G et al.. 2025. Signal-induced NLRP3 phase separation initiates inflammasome activation.. Cell Res 35(6):437-452 PMID: 40164768
- 2. Nakamura MT et al.. 2014. Regulation of energy metabolism by long-chain fatty acids.. Prog Lipid Res 53:124-44 PMID: 24362249
- 3. Fondevila MF et al.. 2022. Inhibition of carnitine palmitoyltransferase 1A in hepatic stellate cells protects against fibrosis.. J Hepatol 77(1):15-28 PMID: 35167910
- 4. Shan J et al.. 2024. Palmitoyltransferase ZDHHC6 promotes colon tumorigenesis by targeting PPARγ-driven lipid biosynthesis via regulating lipidome metabolic reprogramming.. J Exp Clin Cancer Res 43(1):227 PMID: 39148124
- 5. Dai J et al.. 2018. Chemoproteomics reveals baicalin activates hepatic CPT1 to ameliorate diet-induced obesity and hepatic steatosis.. Proc Natl Acad Sci U S A 115(26):E5896-E5905 PMID: 29891721
- 6. Gnoni A et al.. 2020. Carnitine in Human Muscle Bioenergetics: Can Carnitine Supplementation Improve Physical Exercise?. Molecules 25(1) PMID: 31906370
- 7. Jin X et al.. 2025. ZDHHC12 Palmitoylates HDAC8 to Promote the Progression of Hepatocellular Carcinoma Associated with a Diet High in Saturated Fatty Acids.. Adv Sci (Weinh) 12(40):e05702 PMID: 40787880
- 8. Liu Z et al.. 2024. Palmitoylation at a conserved cysteine residue facilitates gasdermin D-mediated pyroptosis and cytokine release.. Proc Natl Acad Sci U S A 121(29):e2400883121 PMID: 38980908
